Seguir
Tea Pemovska, PhD
Tea Pemovska, PhD
Senior Postdoctoral Researcher at Medical University of Vienna
Dirección de correo verificada de meduniwien.ac.at
Título
Citado por
Citado por
Año
Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia
T Pemovska, M Kontro, B Yadav, H Edgren, S Eldfors, A Szwajda, ...
Cancer discovery 3 (12), 1416-1429, 2013
450*2013
Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies
B Yadav, T Pemovska, A Szwajda, E Kulesskiy, M Kontro, R Karjalainen, ...
Scientific reports 4 (1), 1-10, 2014
3202014
Axitinib effectively inhibits BCR-ABL1 (T315I) with a distinct binding conformation
T Pemovska, E Johnson, M Kontro, GA Repasky, J Chen, P Wells, ...
Nature 519 (7541), 102-105, 2015
2632015
Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia
M Kontro, H Kuusanmäki, S Eldfors, T Burmeister, EI Andersson, ...
Leukemia 28 (8), 1738-1742, 2014
1262014
Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions
P Valent, A Orazi, MR Savona, MM Patnaik, F Onida, ...
haematologica 104 (10), 1935, 2019
1252019
JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell–induced protection of AML
R Karjalainen, T Pemovska, M Popa, M Liu, KK Javarappa, MM Majumder, ...
Blood, The Journal of the American Society of Hematology 130 (6), 789-802, 2017
1232017
Recent advances in combinatorial drug screening and synergy scoring
T Pemovska, JW Bigenzahn, G Superti-Furga
Current opinion in pharmacology 42, 102-110, 2018
1032018
HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia
M Kontro, A Kumar, MM Majumder, S Eldfors, A Parsons, T Pemovska, ...
Leukemia 31 (2), 301-309, 2017
892017
Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematological Cancers and Identifies Exceptional Responders
C Kornauth, T Pemovska, GI Vladimer, G Bayer, M Bergmann, S Eder, ...
Cancer discovery, candisc. 0538.2021, 2021
872021
Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling
EI Andersson, S Pützer, B Yadav, O Dufva, S Khan, L He, L Sellner, ...
Leukemia 32 (3), 774-787, 2018
862018
Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML
D Malani, A Murumägi, B Yadav, M Kontro, S Eldfors, A Kumar, ...
Leukemia 31 (5), 1187-1195, 2017
542017
Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia
S Eldfors, H Kuusanmäki, M Kontro, MM Majumder, A Parsons, H Edgren, ...
Leukemia 31 (1), 51-57, 2017
522017
Development of metastatic HER2+ breast cancer is independent of the adaptive immune system
M Ciampricotti, K Vrijland, CS Hau, T Pemovska, CW Doornebal, ...
The Journal of pathology 224 (1), 56-66, 2011
412011
Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL
C Schmidl, GI Vladimer, AF Rendeiro, S Schnabl, T Krausgruber, ...
Nature chemical biology 15 (3), 232-240, 2019
392019
Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing
PO Pietarinen, T Pemovska, M Kontro, B Yadav, JP Mpindi, EI Andersson, ...
Blood cancer journal 5 (5), e309-e309, 2015
352015
From drug response profiling to target addiction scoring in cancer cell models
B Yadav, P Gopalacharyulu, T Pemovska, SA Khan, A Szwajda, J Tang, ...
Disease models & mechanisms 8 (10), 1255-1264, 2015
202015
Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors
PO Pietarinen, CA Eide, P Ayuda-Durán, S Potdar, H Kuusanmäki, ...
Oncotarget 8 (14), 22606, 2017
192017
8‐chloro‐adenosine activity in FLT3‐ITD acute myeloid leukemia
R Buettner, LXT Nguyen, B Kumar, C Morales, C Liu, LS Chen, ...
Journal of cellular physiology 234 (9), 16295-16303, 2019
162019
Core-binding factor leukemia hijacks the T-cell–prone PU. 1 antisense promoter
E van der Kouwe, G Heller, A Czibere, JA Pulikkan, C Agreiter, ...
Blood, The Journal of the American Society of Hematology 138 (15), 1345-1358, 2021
142021
Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
T Heinemann, C Kornauth, Y Severin, GI Vladimer, T Pemovska, ...
Blood Cancer Discovery 3 (6), 502-515, 2022
112022
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20